Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's Bracelet-1 was in HR+/HER2 negative breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 07, 2024 8:39pm

142 Views

Post# 36213452

RE:RE:ONCY's Bracelet-1 was in HR+/HER2 negative breast cancer

This notwithstanding ONCY has committed to releasing the mature OS mBC data in H2 2024 ... which can be anytime now. - making reference in the release perhaos, that OS is still maturing but that the current 2 year + OS data has met the mature survival timeline sufficient for the FDA to grant an Accelerated Approval for pelareorep in mBC.

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide